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Aims: Homozygous familial hypercholesterolaemia (HoFH) is a rare disorder usually caused by mutations
in both alleles of the low-density lipoprotein receptor gene (LDLR). Premature death, often before the age
of 20 years, was a common fate for patients with HoFH prior to the introduction of statins in 1990 and
the use of lipoprotein apheresis. Consequently, HoFH has been widely considered a condition exclusive to
a population comprising very young patients with extremely high LDL cholesterol (LDL-C) levels.
However, recent epidemiologic and genetic studies have shown that the HoFH patient population is far
more diverse in terms of age, LDL-C levels, and genetic aetiology than previously realised. We set out to
investigate the clinical characteristics regarding age and LDL-C ranges of patients with HoFH.
Methods and results: We analysed the data from 3 recent international studies comprising a total of 167
HoFH patients. The age of the patients ranged from 1 to 75 years, and a large proportion of the patients,
both treated and untreated, exhibited LDL-C levels well below the recommended clinical diagnostic
threshold for HoFH. LDL-C levels ranged from 4.4 mmol/L to 27.2 mmol/L (170e1052 mg/dL) for un-
treated patients, and from 2.6 mmol/L to 20.3 mmol/L (101e785 mg/dL) for treated patients. When
patients were stratiﬁed according to LDLR functionality, a similarly wide range of age and LDL-C values
was observed regardless of LDLR mutation status.
Conclusion: These results demonstrate that HoFH is not restricted to very young patients or those with
extremely high LDL-C levels.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Homozygous familial hypercholesterolaemia (HoFH) is a rare
but serious genetic disorder. The condition is caused by mutations
in both alleles of the low-density lipoprotein receptor gene (LDLR),
resulting in severe hypercholesterolaemia (15e25 mmol/L or
600e1000 mg/dL). By virtue of the extremely elevated low-density
lipoprotein cholesterol (LDL-C) levels, patients with HoFH typically
suffer from clinical coronary heart disease manifestations in
childhood that frequently lead to death before the age of 20 yearss, University of the Witwa-
sburg Hospital, 7 York Road,
Raal), b.sjouke@amc.uva.nl
h), Barton.isaac@sanoﬁ.com
Ireland Ltd. This is an open access[1]. In 2001, Goldstein et al. reported that HoFH affects one in one
million individuals. However, recent data from studies in unse-
lected general population samples suggest that the prevalence of
HoFH may have been underestimated [2,3]. The Copenhagen
General Population Study estimated an HoFH prevalence of
approximately one in 160,000 in an unselected European general
population sample, and a recently published study using data from
a nationwide diagnostic center for autosomal dominant hyper-
cholesterolaemia (ADH) in the Netherlands found an HoFH preva-
lence of one in 300,000 based on molecular diagnosis (this
prevalence includes some patients with homozygous apolipopro-
tein B gene [APOB] mutations) [2,3]. Higher rates of HoFH have also
been observed in certain populations where a founder effect or high
rates of consanguinity are present (e.g., French Canadians in
Quebec, Lebanese, South African Afrikaners) [1].
While the original deﬁnition of HoFH by Goldstein and colleagues
has persisted, the disease is now considered to have a more diversearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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not only from mutations in the LDLR gene, but also from rare muta-
tions in the APOB gene and gain-of-function mutations in the pro-
protein convertase subtilisin/kexin type 9 gene (PCSK9). Very rarely,
HoFH can be inherited as a recessive condition known as autosomal
recessive hypercholesterolaemia (ARH), which is the result of muta-
tions in the gene encoding LDL receptor adaptor protein 1 (LDLRAP1)
[4e8]. Moreover, HoFH, as it is molecularly deﬁned, may now include
patientswho are double heterozygotes (those possessingmutations in
two or more of the implicated genes) and compound heterozygotes
(those possessing different mutations in both alleles of one of the
implicated genes). These double heterozygotes and compound het-
erozygotes present with the HoFH phenotype but exhibit more vari-
able low-density lipoprotein cholesterol (LDL-C) levels and, in general,
have a lower risk for atherosclerotic disease [4].
The diagnostic criteria for HoFH have been inconsistent in the
literature. Table 1 in the Data in Brief ﬁle associated with this
publication lists the criteria endorsed by the European Athero-
sclerosis Society (EAS) Consensus Panel on Familial Hyper-
cholesterolaemia [5,9]. The criteria used in this update include a
substantial downward adjustment in threshold LDL-C levels
compared with the deﬁnition by Goldstein et al. [1].
Patients with HoFH are generally considered to be very young. A
South African cohort of patients with HoFH, studied prior to the
availability of statins in 1990, had a mean age of death that was
approximately 18 years. However, after the availability of statins in
1990, the mean age of death had been extended to approximately 33
years. The mean LDL-C level with the use of statins in this cohort was
still quite elevated at 11.7 ± 3.4 mmol/L (452 ± 131 mg/dL) [10]. The
high levels of LDL-C are typical for patients with HoFH and represent
the fundamental dysfunction resulting in an elevated risk of athero-
sclerotic cardiovascular disease. Deposition of cholesterol in patients
with HoFH is proportional to the cholesterol-year scoreda combined
measurement of hypercholesterolaemia severity and dura-
tiondunderscoring the relationship between LDL-C and cardiovascu-
lar risk [5]. Furthermore, LDL-C is, in general, inversely proportionally
correlated with LDLR activity, as evidenced by a study in 32 Italian
patients with HoFH, for whom a negative correlation between LDL-C
and residual LDLR activity was observed (r ¼ 0.66; P < 0.003) [11].
The expansion of the deﬁnition of HoFH, based upon improved
sources of patient data and advances in genetic research, led us to
re-examine longstanding assumptions about the presentation,
prevalence, and distribution of HoFH. The purpose of the present
study is to describe the manifestations and characteristics of HoFH,
with a particular focus on the phenotypic variables of patient age
and range of LDL-C values, by analysing data from three interna-
tional studies published over the last few years describing diverse
groups of patients with HoFH.
2. Methods
The ﬁrst of the 3 studies used for the present analysis consists of
the baseline data pertaining to patients enrolled in a phase 3,
multicentre, international, randomised, double-blind, placebo-
controlled trial (the Genzyme [GZ] HoFH study, ClinicalTrials.gov
number NCT00607373, sponsored by Sanoﬁ Genzyme) comparing
treatment with mipomersen vs placebo in patients with HoFH [12].
It should be noted that the baseline LDL-C levels derived from this
study reﬂect LDL-C levels prior to treatment with mipomersen. The
second study is a published retrospective chart review of patients
treated at two specialised lipid clinics in South Africa (SA study)
between 1972 and 2009 [10]. The third study is the published
analysis of data derived from the national database of patients with
HoFH in the Netherlands, compiled by the Academic Medical
Center in Amsterdam (AMC study), a nationwide DNA diagnosticcentre where patients in the Netherlands are referred for molecular
diagnosis of FH [3].
2.1. Diagnostic criteria
Diagnostic criteria for HoFH used in the GZ HoFH study and SA
study were identical, and largelymirror those of the EAS Consensus
Panel: genetic conﬁrmation of two mutant alleles at the LDLR gene
locus or clinical diagnosis based on untreated LDL-C levels
>13 mmol/L (500 mg/dL) in addition to either xanthoma(s)
observed before 10 years of age or evidence of heterozygous FH in
both parents [10,12]. Diagnostic criteria for the AMC study involved
conﬁrmation of pathogenic mutations for autosomal-dominant FH,
speciﬁc to monogenic manifestations [3].
2.2. Exclusion criteria
Subjects meeting the following criteria were excluded: (1)
subjects actively undergoing lipoprotein apheresis, (2) subjects
with genetic conﬁrmation of a form of HoFH that did not directly
involve the LDLR gene (e.g., APOB), and (3) subjects who were
deceased.
2.3. Phenotypic assessment
LDL-C levels were obtained at each centre frommedical records.
Untreated LDL-C (uLDL-C) refers to the LDL-C level prior to initia-
tion of lipid-lowering therapy (LLT). Treated LDL-C (tLDL-C) refers
to the LDL-C level while the patient was taking the maximally
tolerated available LLT.
Patient age in the GZ HoFH study cohort was derived from the
case report forms at baseline enrollment. Patient age in the AMC
cohort was published online as supplemental data to the original
publication [3]. To be consistent with the GZ HoFH cohort, a con-
servative age was used for patients in the SA lipid clinics, based on
the year that enrollment began in the GZ HoFH study (i.e., 2007)
instead of using patient age at the time of this analysis.
2.4. Molecular assessment
Molecular assessment was undertaken based on classiﬁcation of
LDLR mutations into one of six categories: (1) defective/defective,
(2) defective/negative, (3) negative/negative, (4) defective/unclas-
siﬁed, (5) negative/unclassiﬁed, or (6) unclassiﬁed/unclassiﬁed. An
LDL receptor mutation designated as “negative” is associated with
<2% of LDL uptake in cultured ﬁbroblasts; a receptor mutation
designated as “defective” is associated with 2%e25% of normal
uptake [13]. If the receptor status was not reported or was un-
known in the study publication, it was considered to be
unclassiﬁed.
2.5. Atherosclerotic cardiovascular disease (ASCVD)
We deﬁned ASCVD as any documented history of coronary ar-
tery disease (CAD), aortic valve replacement or repair (AVR), carotid
disease, or peripheral vascular disease. Additionally, we deﬁned
CAD as any general designation in the medical history or if
myocardial infarction, angina pectoris, acute coronary syndrome, or
coronary artery bypass graft (CABG) surgery were speciﬁcally
mentioned.
2.6. Comparative assessment
The diagnostic methodologies of the SA and GZ HoFH studies
were similar, involving initial clinical identiﬁcation of patients (i.e.,
F.J. Raal et al. / Atherosclerosis 248 (2016) 238e244240phenotypic assessment by lipid levels) or by molecular conﬁrma-
tion (if available) after suspicion of HoFH. The AMC study, however,
employed molecular diagnosis only, based on a genetic database of
more than 100,000 individuals. A comparison was therefore un-
dertaken to determine if these two different diagnostic protocols
yielded different results with regard to uLDL-C and tLDL-C levels.
2.7. Statistical analysis
The LDL-C distribution curves demonstrate the overlap of uLDL-
C and tLDL-C values. For the comparison of the AMC cohort and
combined SA and GZ HoFH baseline cohorts, SAS software was
employed to perform a two-sample independent t-test. This com-
parison was chosen because patients in the AMC study had a mo-
lecular diagnosis, whereas the SA and the GZ HoFH baseline cohorts
had predominantly a phenotypic diagnosis with conﬁrmation of
HoFH using molecular diagnosis, if available. Comparisons of the
AMC study with the SAþGZ HoFH studies were conducted for both
uLDL-C and tLDL-C values. The relationship between patient age
and tLDL-C values is presented in the form of scatter plot diagrams
(presented in the Data in Brief ﬁle associated with this publication;
Data in Brief Figs. 1 and 2) [9]. Data regarding patient age at the
time of the recording of uLDL-C values were not always available.
3. Results
An initial total study cohort of 194 patients with HoFH was
identiﬁed for potential inclusion for phenotypic analysis, including
51 patients from the GZ HoFH cohort, 94 from the SA cohort (28 of
the total 122 SA cohort were already included in the GZ HoFH
cohort), and 49 from the AMC cohort (Fig. 1). Study exclusion
criteria resulted in 27 exclusions, leaving a total of 167 study pa-
tients. The 27 excluded patients consisted of 16 patients in the SA
cohort, who were deceased at the time of publication, and 11 pa-
tients in the AMC cohort, including 4 whowere excluded due to the
presence of APOBmutations rather than LDLRmutations, 4 who had
no available LDL-C values, and 3 who were excluded because they
had undergone lipoprotein apheresis at the time the study was
being performed. None of the patients in the GZ HoFH baseline
cohort were excluded.Fig. 1. Flow diagram of patient selection for phenotypic analysis. AMC indicates Academic
zyme; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein chTwenty-eight of the 51 patients included from the GZ HoFH
study were treated and monitored at the South African lipid clinics
participating in the SA study. These 28 patients were not double-
counted in the analysis, but were classiﬁed as being part of the
GZ HoFH cohort. The countries of origin of the 51 patients in the GZ
HoFH baseline cohort were South Africa (n ¼ 28), Brazil (n ¼ 6),
Taiwan (n ¼ 5), the United Kingdom (n ¼ 4), the United States
(n¼ 3), Canada (n¼ 3), and Singapore (n¼ 2). After exclusion of the
GZ HoFH cohort and patients who were deceased at the time of
publication, the SA study contributed 78 patients. The AMC study
contributed 38 patients after excluding the patients as stated.
Of 167 patients for whom uLDL-C and/or tLDL-C data were
available, uLDL-C, tLDL-C, or both were available for analysis in 135,
134, and 102 patients, respectively. LLT regimens were available for
132 of the 167 patients. A statin was included as part of the LLT
regimen in 132 patients, and in 95 (72%) of these the statin was
atorvastatin or rosuvastatin at the maximum recommended
dosage. A summary of patient characteristics, including LLT regi-
mens, is presented in the online supplement (Table S1).
The allelic disposition of patients available for phenotypic
analysis is shown in Table 1. Allelic LDLR gene information was
available in 141 of the 167 patients. Biallelic data associated with
known receptor functionality (i.e., defective/defective, negative/
negative, defective/negative) were available for 131 patients.
Twenty-six patients were designated as unclassiﬁed/unclassiﬁed.
Of the 26 patients, 13 had known allelic information; however, the
functional status (i.e., defective, negative) of those mutations is
currently unknown and is listed as unclassiﬁed. The other 13 pa-
tients who were clinically designated with HoFH had no genetic
information (4 from South African lipid clinics and 9 from the GZ
HoFH study). The age of the overall population (at the time of tLDL-
C measurements) ranged from 1 year to 75 years, (mean age was
31.3 years; standard deviation [SD] 16.2 years). The mean ages
(range) for the GZ HoFH, SA and AMC cohorts were 31.3 (12e53),
29.5 (1e74) and 34.8 (2e75) years, respectively. uLDL-C levels
ranged from 4.4 mmol/L (170 mg/dL) to 27.2 mmol/L (1052 mg/dL),
whereas tLDL-C levels ranged from 2.6 mmol/L (101 mg/dL) to
20.3 mmol/L (785 mg/dL).
The distribution of LDL-C values for the 135 patients with uLDL-
C data and 134 patients with tLDL-C data from all three cohorts isMedical Center in Amsterdam; FDB, familial defective apolipoprotein B-100; GZ, Gen-
olesterol. *Brazil, Taiwan, United Kingdom, the United States, Canada, and Singapore.
Table 1
LDLR functionality status of patients available for phenotypic analysis.
LDLR mutation status (n) Number of Patients included in analysis Comment
Defective/Defective (82) 81 1 patient was excluded due to missing LDL-C values
Defective/Negative (38) 35 3 patients were excluded due to missing LDL-C values
Negative/Negative (15) 15
Defective/Unclassiﬁed (9) 9
Negative/Unclassiﬁed (1) 1
Unclassiﬁed/Unclassiﬁed (26) 26 See text for full description of these patients
LDLR mutational status was available for 171 patients. LDL-C values were not available for 4 of these patients, leaving 167 patients in the ﬁnal analysis.
LDL-C indicates low-density lipoprotein cholesterol; LDLR, low-density lipoprotein receptor gene.
F.J. Raal et al. / Atherosclerosis 248 (2016) 238e244 241shown in Fig. 2. Distribution curves of the LDL-C values for the 102
patients who had paired uLDL-C and tLDL-C are shown in Data in
Brief Fig. 3 [9]. In both distribution curves, the tLDL-C appeared to
have a bimodal distribution.
Comparisons of uLDL-C and tLDL-C values by patient cohort
(AMC vs combined SA þ GZ HoFH) are shown in Fig. 3. uLDL-C
values were available for 29 patients in the AMC cohort (mean
uLDL-C level 12.56 mmol/L [486 mg/dL] [SD 4.99; range
4.4e21.5 mmol/L{170e831 mg/dL}]) and 106 patients in the
SA þ GZ HoFH cohort (mean uLDL-C level 16.36 mmol/L [633 mg/
dL] [SD 4.00; range 8.6e27.2 mmol/L {332e1052 mg/dL}]). The
mean uLDL-C value was 3.8 mmol/L (147 mg/dL) lower in the AMC
cohort compared with the combined SA þ GZ HoFH cohort
(P < 0.0001). tLDL-C values were available for 37 patients in the
AMC cohort (mean tLDL-C level 6.29 mmol/L [243 mg/dL] [SD 3.31;
range 2.6e13.8 mmol/L{101e534 mg/dL}]), and 97 patients in the
SA þ GZ HoFH cohort (mean tLDL-C level, 11.32 mmol/L [438 mg/
dL] [SD 3.61; range 3.1e20.3 mmol/L{120e785 mg/dL}]). The mean
tLDL-C value was 5.03 mmol/L (194 mg/dL) lower in the AMC
cohort compared with the SA þ GZ HoFH cohort (P < 0.0001).
The range of uLDL-C and tLDL-C values stratiﬁed by LDLR
functional mutation status is shown in Fig. 4. A spectrum of LDL-C
levels can be seen across patient groups, regardless of LDLR status.
Even for patients with negative/negative mutations, there was a
wide range in age (1e61 years) and tLDL-C levels (9e20.3 mmol/L
[348e784 mg/dL]), with a high degree of overlap in age and tLDL-
C between defective/defective and defective/negative allelic
status.
ASCVD was documented in the medical history for 64 of the 167Fig. 2. Distribution of LDL-C values by treatment status for patients in all cohorts with u
cholesterol; tLDL-C, treated low-density lipoprotein cholesterol; uLDL-C, untreated low-dens
solid line: distribution of patients with a particular uLDL-C.patients (38.3%). Mean age at the time of ﬁrst ASCVD event was 26.2
years (SD 12.8 years), with a range of 6e63 years. CAD was docu-
mented in 30 patients, 19 patients had undergone AVR, and 34 had
undergone CABG surgery at amean age of 27.6, 25.9, and 28.6 years,
respectively. uLDL-C levels were available for 58 of these patients,
with a mean value of 16.7 mmol/L (645.8 mg/dL), an SD of
4.35 mmol/L (168.2 mg/dL), and a range of 6.9 mmol/L to
25.2 mmol/L (266.8e974.5 mg/dL). Of the 103 patients without a
documented history of ASCVD, only 77 had a documented uLDL-C
value. The mean uLDL-C for those without ASCVD was
14.6 mmol/L (564.6 mg/dL), with an SD of 4.37 mmol/L (170.0 mg/
dL) and with a range of 4.4 mmol/L to 27.2 mmol/L
(170.1e1051.8 mg/dL). The difference in uLDL-C between patients
with and without ASCVD was statistically signiﬁcant (P ¼ 0.0066).
Seven patients with a history of ASCVD (11%) had negative/negative
LDLR functional status. The mean age of these 7 patients was 28
years (range 10e61 years), with an SD of 16.8 years. Of these 7
patients, 6 had a known uLDL-C, with a mean of 21.7 mmol/L
(839.1 mg/dL), an SD of 3.85 mmol/L (148.9 mg/dL), and a range of
14.8 mmol/L to 25.2 mmol/L (572.3e974.5 mg/dL). Thirty-four pa-
tients with a history of ASCVD (53%) had defective/defective LDLR
functional status. The mean age of these 34 patients was 29.4 years
(SD 13 years; range 6e63 years). Of these 34 patients, 31 had a
known uLDL-C with a mean value of 15.3 mmol/L (591.6 mg/dL), an
SD of 3.88 mmol/L (150.0 mg/dL), and a range of 6.9 mmol/L to
23.6 mmol/L (266.8e912 g mg/dL). The mean uLDLs for those pa-
tients without ASCVD for negative/negative and defective/defective
LDLR functional status were 18.6 mmol/L (719.3 mg/dL) and
12.6 mmol/L (487.2 mg/dL), respectively.LDL-C (n ¼ 135) or tLDL-C data (n ¼ 134). LDL-C indicates low-density lipoprotein
ity lipoprotein cholesterol. Dotted line: distribution of patients with a particular tLDL-C;
Fig. 3. uLDL-C vs tLDL-C values by patient cohort. GZ indicates Genzyme; HoFH, homozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; tLDL-C,
treated low-density lipoprotein cholesterol; uLDL-C, untreated low-density lipoprotein cholesterol.
Fig. 4. uLDL-C vs tLDL-C values for patients in all cohorts stratiﬁed by receptor functional status. The bottom and top of the box represent the ﬁrst and third quartiles. The band
inside the box is the median. The ends of the whiskers represent minimum and maximum values. The mean is represented by the dot. Def/Def indicates defective/defective; Def/
Uncl, defective/unclassiﬁed; LDL-C, low-density lipoprotein cholesterol; Neg/Def, negative/defective; Neg/Neg, negative/negative; Neg/Uncl, negative/unclassiﬁed; tLDL-C, treated
low-density lipoprotein cholesterol; uLDL-C, untreated low-density lipoprotein cholesterol; Uncl/Uncl, unclassiﬁed/unclassiﬁed.
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Together, the three cohorts reported in this analysis represent
the largest group of patients with HoFH to be collectively evaluated
for phenotypic description to date. The patients with HoFH due to
LDLR mutations in this analysis challenge the assumption that pa-
tients with HoFH are generally young or have markedly elevated
LDL-C levels, despite the exclusion of patients with APOB muta-
tions, who tend to have a milder phenotype [14,15]. Indeed, this
group of 167 patients with HoFH ranged in age from 1 to 75 years,
and included 21 patients older than 50 years. LDL-C levels ranged
from4.4mmol/L to 27.2mmol/L (170e1052mg/dL) prior to LLT, and
from 2.6 mmol/L to 20.3 mmol/L (101e785 mg/dL) during LLT.
When the three cohorts were pooled, a substantial proportion of
untreated patients (36, or 26.7%) with LDL-C levels below the rec-
ommended diagnostic threshold of >13 mmol/L (500 mg/dL), andof treated patients (41, or 30.6%) with LDL-C levels below the
diagnostic threshold of 8 mmol/L (300 mg/dL) was observed.
A high degree of variability was also observed in the response to
LLT and between LDLR functionality, patient age, and LDL-C levels.
Patients with more severe LDLR dysfunction (i.e., negative rather
than defective) had serum LDL-C levels that tended to cluster in a
higher range than patients with residual LDLR function. However,
patients in both groups exhibited a wide range of LDL-C levels,
particularly while receiving LLT. The source of the variability in
phenotype is unknown, but is likely multifactorial, involving mul-
tiple genes and environmental factors [3,16e18]. It should be noted
that some patients with the more severe receptor-negative desig-
nation may have died at a very young age and thus would not have
been available for this analysis, potentially creating a selection bias.
Nevertheless, the extent of this selection bias is likely limited
because 15 negative/negative patients with HoFH were included in
F.J. Raal et al. / Atherosclerosis 248 (2016) 238e244 243this cohort.
More than one-third of the patients had some form of ASCVD
documented in the available medical histories. The mean age of
26.2 years for the ﬁrst ASCVD event was very similar to the mean
age of the ﬁrst reported AVR, CABG surgery, and CAD events. Un-
treated LDL-C values were higher in those with a history of an
ASCVD event compared with patients who did not have a history of
ASCVD (16.7 vs 14.6 mmol/L [645.8 vs 564.6 mg/dL]). Comparing
LDLR functional status between those with and those without a
history of ASCVD, uLDL-C values were higher for those patients
with an ASCVD event. The uLDL-C for patients with negative/
negative mutations was 21.7 mmol/L (839.1 mg/dL) for those with a
history of ASCVD vs 18.6 mmol/L (332.6 mg/dL) for those without a
history of ASCVD. The uLDL-C for patients with defective/defective
mutations was 15.3 mmol/L (591.6 mg/dL) for those with a history
of ASCVD vs 12.6 mmol/L (487.2 mg/dL) for those without a history
of ASCVD. This difference was statistically signiﬁcant (P ¼ 0.0055).
We had the opportunity to determine if there might be a dif-
ference in phenotypic versus genotypic presentation, because the
AMC cohort used molecular diagnosis to identify patients with
HoFH, while the SA and GZ HoFH cohorts were diagnosed by clin-
ical or genetic methods. The molecularly diagnosed AMC cohort
had a mean uLDL-C level that was 3.8 mmol/L (147 mg/dL) lower
than the other 2 cohorts combined (P < 0.0001). Based on these
data, onemight conclude thatmolecular diagnosis is more sensitive
for detecting HoFH. In our view, however, the fact that LDL-C levels
are relatively lower in the group with a molecular diagnosis
compared with the group who were diagnosed clinically un-
derscores the large phenotypic variability in HoFH, but does not
give credence to an assumption that molecular diagnosis is a
preferable diagnostic method, although a molecular diagnosis of
the causal mutations(s) may provide additional motivation for
some patients to implement appropriate treatment [19]. More than
1600 known LDLR mutations that result in FH have been identiﬁed
to date. However, a negative genetic test result does not exclude
HoFH because at least 20% of patients with clinically deﬁnite FH are
not found to have a mutation despite an exhaustive search [19,20].
The results of our analysis are compatible with previously
published reports in patients with heterozygous FH. Bertolini and
coworkers evaluated the phenotypes in 832 Italian patients with
molecularly deﬁned ADH and showed that the LDL-C levels varied
widely among the ADH patients [16].
We observed a wide age range in the patients with HoFH, and
the eldest person included in this analysis was 75 years old. The
ﬁnding that patients with HoFH might reach this age was also
highlighted by a recently published report about a patient with
HoFH who survived until the age of 85 years [21].
This retrospective analysis has some limitations that should be
noted. First, the LLT regimens were not uniform for every patient.
We made the assumption that the LLTs in these patients were
administered at the maximum tolerated dosage. Second, patient
age at the time that the uLDL-C levels were measured was not al-
ways available. Thirdly, the age of patients from the GZ HoFH study
was used to conservatively estimate the age of the patients in the
SA cohort to the year 2007.We do feel, however, that the ages of the
patients presented here might actually be at the lower end because
many of these patients are still alive and older now than the age
provided in this analysis.
5. Conclusions
Patients with HoFH possessing varying degrees of LDLR
dysfunction exhibited a broad range of LDL-C levels regardless of
whether or not they had received LLT. Traditionally, patients with
HoFH have invariably been considered to be young and to haveexceedingly high LDL-C levels; however, our study refutes this
notion. Because the HoFH patient population is diverse regarding
age and LDL-C levels, consideration of a diagnosis of HoFH should
not be limited to the very young or to patients with extremely high
LDL-C levels.
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